



Tukysa (tucatinib)
Prior Authorization Request Form



Caterpillar Prescription Drug Benefit
 Phone: 877-228-7909 Fax: 800-424-7640

Instructions: Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

URGENT

MEMBER INFORMATION		
LAST NAME:	FIRST NAME:	
PHONE NUMBER:	DATE OF BIRTH:	
STREET ADDRESS:		
CITY:	STATE:	ZIP CODE:
PATIENT INSURANCE ID NUMBER:		

MALE FEMALE HEIGHT (IN/CM): _____ WEIGHT (LB/KG): _____ ALLERGIES: _____

IF YOU ARE NOT THE PATIENT OR THE PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI DISCLOSURE AUTHORIZATION FORM WITH THIS REQUEST WHICH CAN BE FOUND AT THE FOLLOWING LINK: [HTTPS://MAGELLANRX.COM/MEMBER/EXTERNAL/COMMERCIAL/COMMON/DOC/EN-US/PHI DISCLOSURE AUTHORIZATION.PDF](https://MAGELLANRX.COM/MEMBER/EXTERNAL/COMMERCIAL/COMMON/DOC/EN-US/PHI_DISCLOSURE_AUTHORIZATION.PDF)

PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE): _____
 AUTHORIZED REPRESENTATIVE'S PHONE NUMBER: _____

PRESCRIBER INFORMATION		
LAST NAME:	FIRST NAME:	
PRESCRIBER SPECIALTY:	EMAIL ADDRESS:	
NPI NUMBER:	DEA NUMBER:	
PHONE NUMBER:	FAX NUMBER:	
STREET ADDRESS:		
CITY:	STATE:	ZIP CODE:
REQUESTOR (if different than prescriber):	OFFICE CONTACT PERSON:	

MEDICATION OR MEDICAL DISPENSING INFORMATION			
MEDICATION NAME:			
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:
<input type="checkbox"/> NEW THERAPY	<input type="checkbox"/> RENEWAL	IF RENEWAL: DATE THERAPY INITIATED:	
DURATION OF THERAPY (SPECIFIC DATES):			

Continued on next page





Tukysa (tucatinib)
Prior Authorization Request Form



Caterpillar Prescription Drug Benefit
 Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ MEMBER'S FIRST NAME: _____

1. HAS THE PATIENT TRIED ANY OTHER MEDICATIONS FOR THIS CONDITION? <input type="checkbox"/> YES (if yes, complete below) <input type="checkbox"/> NO		
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE): 	DURATION OF THERAPY (SPECIFY DATES): 	RESPONSE/REASON FOR FAILURE/ALLERGY:
2. LIST DIAGNOSES: <input type="checkbox"/> Advanced, unresectable HER2-positive breast cancer <input type="checkbox"/> Metastatic HER2-positive breast cancer <input type="checkbox"/> Other diagnosis: _____ ICD-10 _____		ICD-10:
3. REQUIRED CLINICAL INFORMATION: PLEASE PROVIDE ALL RELEVANT CLINICAL INFORMATION TO SUPPORT A PRIOR AUTHORIZATION.		
Clinical Information: Is this drug being prescribed to this patient as part of a treatment regimen specified within a sponsored clinical trial? <input type="checkbox"/> Yes <input type="checkbox"/> No Has patient been previously treated with one or more antiHER2-based regimens(trastuzumab, pertuzumab and trastuzumab emtansine(T-DM1 or Kadcyla®) in the metastatic setting? <input type="checkbox"/> Yes <input type="checkbox"/> No Will patient use Tukysa(tucatinib) in combination with trastuzumab AND capecitabine? <input type="checkbox"/> Yes <input type="checkbox"/> No Has patient had prior use of Lenvima(lapatinib) in the past 12 months? <input type="checkbox"/> Yes <input type="checkbox"/> No If patient had prior use of Lenvima(lapatinib) in the past 12 months, did the patient receive less than 22 days of therapy? <input type="checkbox"/> Yes <input type="checkbox"/> No Did the patient discontinue the Lenvima(lapatinib) for reasons other than disease progression or toxicity? <input type="checkbox"/> Yes <input type="checkbox"/> No Has patient had prior use of neratinib(Nerlynx), afatinib(Gilotrif) or other HER2 EGFR or HER2 tyrosine kinase inhibitors? <input type="checkbox"/> Yes <input type="checkbox"/> No Has patient had prior use of capecitabine or other fluoropyrimidines for metastatic disease? <input type="checkbox"/> Yes <input type="checkbox"/> No If Yes, Was capecitabine or other fluoropyrimidines used in adjuvant/neoadjuvant treatment less than 12months ago? <input type="checkbox"/> Yes <input type="checkbox"/> No If patient has had prior use of capecitabine or other fluoropyrimidines for metastatic disease, did the patient receive less than 22 days of therapy? <input type="checkbox"/> Yes <input type="checkbox"/> No Did the patient discontinue prior use of capecitabine or other fluoropyrimidines for metastatic disease for reasons other than disease progression or toxicity? <input type="checkbox"/> Yes <input type="checkbox"/> No Does the patient have leptomeningeal disease? <input type="checkbox"/> Yes <input type="checkbox"/> No		





Tukysa (tucatinib)
Prior Authorization Request Form
 Caterpillar Prescription Drug Benefit
 Phone: 877-228-7909 Fax: 800-424-7640



MEMBER'S LAST NAME: _____ **MEMBER'S FIRST NAME:** _____

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: Not all drugs/diagnosis are covered on all plans. This request may be denied unless all required information is received.

ATTESTATION: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

Prescriber Signature or Electronic I.D. Verification: _____ **Date:** _____

CONFIDENTIALITY NOTICE: The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX) and arrange for the return or destruction of these documents.

FAX THIS FORM TO: 800-424-7640

MAIL REQUESTS TO: Magellan Rx Management Prior Authorization Program; c/o Magellan Health, Inc.
 4801 E. Washington Street, Phoenix, AZ 85034
 Phone: 877-228-7909

